Cargando…

The GPER Agonist LNS8801 Induces Mitotic Arrest and Apoptosis in Uveal Melanoma Cells

Uveal melanoma is the most common primary intraocular malignancy in adults and has a high incidence of metastatic disease. Current treatments have shown limited clinical activity in patients with uveal melanoma with metastasis and there is an urgent need for new effective therapies. Recent findings...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ambrosini, Grazia, Natale, Christopher A., Musi, Elgilda, Garyantes, Tina, Schwartz, Gary K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075232/ https://www.ncbi.nlm.nih.gov/pubmed/37035582 http://dx.doi.org/10.1158/2767-9764.CRC-22-0399

Ejemplares similares

BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells
por: Ambrosini, Grazia, et al.
Publicado: (2015)

Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype
por: Ho, Alan L., et al.
Publicado: (2012)

LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
por: Lee, Inyoung, et al.
Publicado: (2023)

Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target
por: Bao, Riyue, et al.
Publicado: (2020)

A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma
por: Shoushtari, Alexander N., et al.
Publicado: (2021)

Tris DBA palladium is an orally available inhibitor of GNAQ mutant uveal melanoma in vivo
por: Musi, Elgilda, et al.
Publicado: (2019)

University of Cambridge deploys Procket Networks' PRO/8801
Publicado: (2003)

Intermittent MEK inhibition for the treatment of metastatic uveal melanoma
por: Khan, Shaheer, et al.
Publicado: (2022)

Setting up the LNS library management system
por: Agnello, G
Publicado: (1995)

Installation of ECR2 at LNS and Preliminary tests
por: Gammino, S, et al.
Publicado: (1999)

Correlation of functional and radioligand binding characteristics of GPER ligands confirming aldosterone as a GPER agonist
por: Ding, Qingming, et al.
Publicado: (2022)

Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma
por: Chua, Vivian, et al.
Publicado: (2019)

Clinical profile and demographic distribution of band shaped keratopathy in India: A study of 8801 patients
por: Das, Anthony V, et al.
Publicado: (2022)

Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy
por: Khan, Shaheer, et al.
Publicado: (2022)

Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma
por: Patwardhan, Parag P., et al.
Publicado: (2015)

Uveal Melanoma
por: Papastefanou, Vasilios P., et al.
Publicado: (2011)

Uveal Melanoma
por: Pfeffer, Ulrich
Publicado: (2019)

Application of Ferroelectric Cathodes to Enhance the Ion Yield in the Caesar Source at LNS
por: Boscolo, I, et al.
Publicado: (2000)

Prognostic Value of Metastatic No.8p LNs in Patients with Gastric Cancer
por: Guo, Dong-Jiao, et al.
Publicado: (2015)

Effects of the selective GPER1 agonist G1 on bone growth
por: Iravani, Maryam, et al.
Publicado: (2019)

Molecular Characterization of the Dual Effect of the GPER Agonist G-1 in Glioblastoma
por: Hirtz, Alex, et al.
Publicado: (2022)

Plastic Classification Using Optical Parameter Features Measured with the TMF8801 Direct Time-of-Flight Depth Sensor
por: Becker, Cienna N., et al.
Publicado: (2023)

MRI of Uveal Melanoma
por: Ferreira, Teresa A., et al.
Publicado: (2019)

The biology of uveal melanoma
por: Amaro, Adriana, et al.
Publicado: (2017)

Uveal Melanoma Metastasis
por: Rossi, Ernesto, et al.
Publicado: (2021)

First Beam from the TRASCO Intense Proton Source (TRIPS) at INFN-LNS
por: Ciavola, G, et al.
Publicado: (2001)

Study and operation of the injection, acceleration and extraction processes for the LNS superconducting cyclotron commissioning
por: Rifuggiato, D, et al.
Publicado: (1995)

Metastatic disease from uveal melanoma: treatment options and future prospects
por: Carvajal, Richard D, et al.
Publicado: (2017)

Pembrolizumab as first-line treatment for metastatic uveal melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?
por: Rossi, Ernesto, et al.
Publicado: (2019)

Gamma knife radiosurgery for the treatment of uveal melanoma and uveal metastases
por: Reynolds, Margaret M., et al.
Publicado: (2017)

Exoresection and Endoresection for Uveal Melanoma
por: Gündüz, Kaan, et al.
Publicado: (2010)

Uveal melanoma: Estimating prognosis
por: Kaliki, Swathi, et al.
Publicado: (2015)

YAP as oncotarget in uveal melanoma
por: Yu, Fa-Xing, et al.
Publicado: (2014)

DNA Methylation and Uveal Melanoma
por: Yang, Zhi-Kun, et al.
Publicado: (2018)

Role of Epigenetics in Uveal Melanoma
por: Li, Yongyun, et al.
Publicado: (2017)

Epidemiology of uveal melanoma in Brazil
por: Lucena, Evandro, et al.
Publicado: (2020)

Spliceosome Mutations in Uveal Melanoma
por: Nguyen, Josephine Q.N., et al.
Publicado: (2020)

Multicentric recurrent uveal melanoma
por: Menon, Vikas, et al.
Publicado: (2020)

Animal Models of Uveal Melanoma
por: Uner, Ogul E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jumdpnnv9kjv457guda997tt2r